RENAL HANDLING OF CARBOPLATIN

被引:27
作者
SORENSEN, BT
STROMGREN, A
JAKOBSEN, P
NIELSEN, JT
ANDERSEN, LS
JAKOBSEN, A
机构
[1] AARHUS UNIV HOSP,DEPT CLIN PHYSIOL & NUCL MED,DK-8000 AARHUS,DENMARK
[2] AARHUS UNIV,INST PHARMACOL,DK-8000 AARHUS,DENMARK
关键词
CARBOPLATIN; PHARMACOKINETICS;
D O I
10.1007/BF00686302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mechanism for renal handling of carboplatin was studied in 17 ovarian cancer patients treated with a combination of carboplatin and cyclophosphamide. Carboplatin and [Cr-51]-ethylenediaminetetraacetic acid (EDTA) renal clearances were measured simultaneously during short intervals of from 45 to 120 min. A total of 131 clearance intervals were analyzed during 35 chemotherapy courses. The carboplatin/[Cr-51]-EDTA clearance ratio (R) served as an indicator of the net tubular reabsorption (R < 1) or secretion (R > 1). The R value was calculated for each sampling interval. No significant difference was found between interpatient and intertreatment variation. The intertreatment variation as tested against the variation in the short intervals by an F-test was highly significant. We calculated the average R value for each treatment and consequently based our results on a total of 35 observations. The mean R value was 0.77 (t-test for R = 1; P < 0.001). We conclude that the renal elimination of carboplatin takes place by glomerular filtration followed by tubular reabsorption.
引用
收藏
页码:317 / 320
页数:4
相关论文
共 11 条
[2]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[3]   PHASE-I STUDIES WITH CARBOPLATIN AT THE ROYAL-MARSDEN-HOSPITAL [J].
CALVERT, AH ;
HARLAND, SJ ;
NEWELL, DR ;
SIDDIK, ZH ;
HARRAP, KR .
CANCER TREATMENT REVIEWS, 1985, 12 :51-57
[4]   LIQUID-CHROMATOGRAPHIC PROCEDURE FOR THE QUANTITATIVE-ANALYSIS OF CARBOPLATIN IN BEAGLE DOG PLASMA ULTRAFILTRATE [J].
DUNCAN, GF ;
FAULKNER, HC ;
FARMEN, RH ;
PITTMAN, KA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1988, 77 (03) :273-276
[5]  
ELFERINK F, 1987, CANCER TREAT REP, V71, P1231
[6]  
FREEDMAN LS, 1988, CANCER CHEMOTH PHARM, V22, P95
[7]   THE DISPOSITION OF CARBOPLATIN IN OVARIAN-CANCER PATIENTS [J].
GAVER, RC ;
COLOMBO, N ;
GREEN, MD ;
GEORGE, AM ;
DEEB, G ;
MORRIS, AD ;
CANETTA, RM ;
SPEYER, JL ;
FARMEN, RH ;
MUGGIA, FM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1988, 22 (03) :263-270
[8]  
HARLAND SJ, 1984, CANCER RES, V44, P1693
[9]  
JACOBS C, 1980, CANCER TREAT REP, V64, P1223
[10]  
REECE PA, 1987, CANCER CHEMOTH PHARM, V19, P326